くすりのしおり

Injection
Revised: 7/2020

The information on this sheet is based on approvals granted by the Japanese regulatory authority. Approval details may vary by country. Medicines have adverse reactions (risks) as well as efficacies (benefits). It is important to minimize adverse reactions and maximize efficacy. To obtain a better therapeutic response, patients should understand their medication and cooperate with the treatment.
Brand name :
Beovu kit for intravitreal injection 120mg/mL
 Active ingredient:
Brolucizumab(genetical recombination)
 Dosage form:
Injection
 Print on wrapping:

Effects of this medicine

This medicine inhibits the effect of VEGF (vascular endothelial growth factor), which is involved in pathological angiogenesis and leakage of blood vessels in the eye. It consequently suppresses the formation of new unnecessary blood vessels and leakage of water from blood vessels, and consequently maintains or improves visual acuity.
It is usually used to treat age-related macular degeneration with subfoveal choroidal neovascularization.

Before using this medicine, be sure to tell your doctor and pharmacist

  • If you have previously experienced any allergic reactions (itch, rash, etc.) to any medicines.
    If you have: infection or suspicion of infection around the eye or eye, inflammation in the eye.
  • If you are pregnant or breastfeeding.
  • If you are taking any other medicinal products. (Some medicines may interact to enhance or diminish medicinal effects. Beware of over-the-counter medicines and dietary supplements as well as other prescription medicines.)

Dosing schedule (How to take this medicine)

  • Your dosing schedule prescribed by your doctor is ((        to be written by a healthcare professional))
  • In general, administer by intraocular (intravitreal) injection once a month for the 3 months in a row (a total of 3 times). After 3 initial doses, inject every 3 months. The treatment interval should be at least 2 months.
  • Depending on your response to the treatment, this medicine may be administered over a long time.

Precautions while taking this medicine

  • Since transient impaired letters/shape or abnormal vision may occur following the injection, avoid performing dangerous operations such as driving a car or operating machinery until resolution of the symptom.

Possible adverse reactions to this medicine

The most commonly reported adverse reactions include conjunctival bleeding and intraocular inflammation (iritis, uveitis, etc.). If any of these symptoms occur, consult with your doctor or pharmacist.
The symptoms described below are rarely seen as initial symptoms of the adverse reactions indicated in brackets. If any of these symptoms occur, see your doctor immediately.
  • eye pain, foreign body sensation in the eye, decreased visual acuity  [eye disorder (endophthalmitis, intraocular inflammation, retinal pigment epithelium tear, retinal detachment, retinal tear, retinal artery occlusion, retinal vasculitis, retinal vascular occlusion)]
  • headache, temporarily impaired consciousness, chest pain [arterial thromboembolism (stroke, myocardial ischemia)]
The above symptoms do not describe all the adverse reactions to this medicine. Consult with your doctor or pharmacist if you notice any symptoms of concern other than those listed above.

Storage conditions and other information

For healthcare professional use only : Day Month Year

For further information, talk to your doctor or pharmacist.